1
项与 RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床试验Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
The purpose of this study was to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.
100 项与 RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床结果
100 项与 RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases) 相关的转化医学
100 项与 RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases) 相关的专利(医药)
100 项与 RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases) 相关的药物交易